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Purpose: Fluconazole-associated liver injury is
estimated to occur in <10% of patients;
however, the effect of weight-based fluconazole
dosing on liver injury has not been assessed.
This study evaluated how often patients met
Drug Induced Liver Injury Network (DILIN)
criteria when receiving fluconazole daily doses
of <6mg/kg versus ≥6mg/kg.
Methods: This multi-center, retrospective cohort
study was performed in critically-ill fluconazole
recipients hospitalized from January 2009 to
December 2012. It included patients who
received ≥3 fluconazole doses with ≥1 dose
administered in the intensive care unit. Patients
were excluded if they were pregnant, presented
with acetaminophen toxicity, received
fluconazole within 1 week of liver
transplantation, or missed >1 fluconazole dose
during therapy. We compared liver function tests
(LFTs) upon fluconazole initiation to peak LFTs
within 2 weeks after fluconazole discontinuation
using DILIN criteria. The Fisher’s exact test was
used to detect differences in the primary
outcome of patients meeting DILIN criteria by
weight-based dosing as well as in subgroups of
patients with kidney dysfunction, liver disease,
septic shock, and those receiving a loading
dose.
Results: Two-hundred and forty-eight of 767
patients met inclusion criteria; 90% had a
documented fungal infection or received empiric
therapy for suspected invasive candidiasis. Of
the 199 patients receiving <6 mg/kg of
fluconazole, 55% met DILIN criteria versus
46.9% of the 49 patients in the ≥6 mg/kg cohort
(p=0.20). Only 14.5% of patients meeting DILIN
criteria also met the definition for hepatocellular
damage. In analysis of subgroups, 77.3% of
patients with cirrhosis and 76.3% with septic
shock met DILIN criteria (p<0.001 for both
compared to those without these conditions).
Conclusions: Weight-based fluconazole dosing
did not affect the number of critically-ill
recipients who met DILIN criteria. However,
DILIN criteria may overestimate the incidence of
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Primary Objective: To evaluate the incidence of patients meeting DILIN
criteria with weight-based fluconazole dosing (<6mg/kg vs. ≥6mg/kg) in an
ICU population.
Secondary Objective: To assess the affect of the following characteristics on
development of fluconazole-associated drug induced liver injury (DILI): renal
dysfunction (CrCl<50 mL/min), cirrhosis, septic shock, and patients receiving
a loading dose of fluconazole.
This is a multicenter, retrospective cohort study of ICU patients at University
Hospital or Audie L. Murphy Veterans Affairs Hospital. Patients included
received fluconazole for ≥3 days with ≥1 dose given in the ICU. Serum
creatinine and liver function panel were collected the day of or day prior to
fluconazole initiation and ≥1 follow-up lab within 2 weeks of discontinuation.
If available, labs collected on days 3, 7, and weekly thereafter were included.
A meta-analysis of ten randomized, controlled trials, including 697 patients,
evaluated the incidence of hepatotoxicity with fluconazole when used for
treatment of invasive fungal infections.1 Ten percent of patients had increased
liver transaminases, of which only 0.7% discontinued fluconazole. However,
the definition of hepatotoxicity varied greatly between each included study.
The DILIN has developed standardized definitions to identify cases of drug-
induced liver injury. At this time, studies have not systematically evaluated the
effect of weight-based fluconazole dosing on liver injury.
Table 4. Number of Patients Meeting DILIN Criteria and Type of Injury
Fluconazole <6 mg/kg Fluconazole ≥6 mg/kg
Patients meeting DILIN criteriaa 110 (55%) 23 (46.9%)
Hepatocellular 31 (28.1%) 5  (21.7%)
Mixed 14 (12.7%) 3  (13.0%)
Cholestatic 65 (59.1%) 15 (65.2%)
NOTE. Data is for number (%) of patients.
ap=0.20
Table 5. Number of Patients Meeting DILIN Criteria by Subgroups
Fluconazole <6 mg/kg Fluconazole ≥6 mg/kg
CrCl <50 mL/min 52 (61.90%) 8  (61.54%)
Cirrhosis 60 (75.95%) 8  (88.89%)
Sepsis at ICU Admission 78 (56.52%) 17 (45.95%)
Septic Shocka 51 (85.00%) 10 (50.00%)
Loading Dose Received 23 (51.11%) 2  (33.33%)
NOTE. Data is for number (%) of patients.
ap<0.05





Creatinine Clearance (CrCl) <50 mL/mina 84  (42.4%) 13 (26%)
Cirrhosisa 79  (39.7%) 9  (18.3%)
Sepsis at ICU admission 138 (69.3%) 37 (75.5%)
Septic Shock 60 (30.1%) 20 (40.8%)
Number of patients receiving loading dose (LD) 45  (23%) 6  (12%)
Number of patients receiving LD >12 mg/kga 0   (0.0%) 5  (10.2%)
NOTE. Data is for number (%) of patients.
ap<0.05





Age, years 57 (49-64) 56 (46.5-64)
Weight, kga 80.3 (69.4-97.6) 59.1 (50.8-64.3)
Height, cma 172.7 (162.6-180.0) 167.6 (157.5-172.5)
Creatinine clearance, mL/mina 59.8 (30.7-92.8) 76.0 (46.8-121.0)
Average maintenance dose, mga 222 (200-400) 400 (400-508)
Weight based average dose, mg/kga 3.44 (2.52-4.56) 7.18 (6.53-8.81)
Weight based loading dose, mg/kga 6.01 (4.50-8.40) 14.6 (11.8-19.1)
NOTE. Data is for Median (IQR).
ap<0.05
All ICU patients initiated on fluconazole between
January 1, 2009 and December 31, 2012 (n=767)
Patients who met 
inclusion criteria 
(n=248)
Fluconazole for ≥3 days 




Received fluconazole for candiduria (n=70)
Fluconazole received within 1 week of liver transplant (n=76)
Missing baseline or follow-up liver function tests (n=155)
Missing ≥2 doses of fluconazole during treatment period or 
receiving fluconazole prior to hospital admission (n=188)
Table 1. Drug-Induced Liver Injury Definition2
• AST or ALT >5x ULN or >5x baseline abnormal value, or
• Alkaline phosphatase (ALP) >2x ULN (or pretreatment baseline if baseline level is 
abnormal), or
• Total serum bilirubin level >2.5 mg/dL along with elevated AST or ALT or ALP,  or
• INR >1.5 with elevated AST or ALT or ALP
Type of Injury                           
• Hepatocellular R ≥ 5
• Cholestatic R ≤ 5
• Mixed R<2 or R<5
NOTE: R = (ALT/ULN)/(alkaline phosphatase/ULN)
Statistical analysis with JMP© 10.0 (SAS Corporation, Cary, NC)
• Nominal data analyzed using Chi-squared or Fisher’s exact, as appropriate.
• Continuous variables tested for normality using the Shapiro-Wilk W Test.
• Non-parametric continuous data analyzed using the Wilcoxon rank sum.
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While 90% of patients included in the study were on fluconazole for empiric
treatment or had a documented fungal infection, less than 20% received
fluconazole ≥6 mg/kg.
This multicenter, retrospective cohort study suggests that there is no
increased risk of patients meeting DILIN criteria with higher doses of
fluconazole. However, in this study, 50% of patients met the DILIN criteria.
This high rate of possible DILI may be because the definition evaluates
increases in ALP, total serum bilirubin, and INR. However, previous literature
shows fluconazole-induced liver injury with primary increases in AST and ALT
which indicates a hepatocellular pattern of damage.3
Currently, there are no standardized tools currently available to evaluate DILI
in ICU patients. If clinicians use DILIN criteria in the ICU, it may lead to an
overestimation of DILI which may result in inappropriate discontinuation of
necessary drugs or inappropriate dosage reduction.
It is noteworthy that a large number of patients did not receive fluconazole
≥6mg/kg. The overall average weight of the patients in our study was 76 kg
and the overall average maintenance dose of fluconazole was 350 mg/day
(about 4.6mg/kg overall). Furthermore, the median average maintenance
dose was only 400 mg in the ≥6mg/kg dose group. This finding may indicate
that similar doses were given to all patients, regardless of weight. Patients
were more likely to be placed in the ≥6mg/kg group if they were of lower
weight.
Limitations
1) Exclusion of 155 patients due to missing labs. This limitation was
minimized by including patients with baseline labs the day of or day prior
to fluconazole initiation and ≥1 follow-up lab within two weeks of
discontinuation.
2) DILIN excluded patients with previous liver or bone marrow transplant,
underlying liver disease defined as autoimmune liver disease, or
sclerosing cholangitis. However, only a small number of patients met this
criteria and labs were only followed for up to two weeks after fluconazole
discontinuation.
Clinicians should be cautious of using DILIN criteria in the ICU setting
because it may overestimate hepatotoxicity. DILIN criteria should be followed
with causality assessment in patients and investigation into other causes of
elevated LFTs in the ICU setting. Investigations for more specific scales in
ICU patients need to be created and validated. Retrospective studies should
be conducted applying these criteria to biopsy-confirmed cases of drug-
induced liver injury in critically-ill patients where true sensitivity and specificity
tests can be performed.
Statistics
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